Tarceva® ( erlotinib )
Indicated for :the treatment of locally advanced or metastatic non-small cell lung cancer that has failed prior chemotherapy
Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor
2. Tarceva
Generic name: Erlotinib
Brand name: Tarceva®
FDA Approval Date: November 18,
2004
3. Tarceva
Indicated for :the treatment of locally
advanced or metastatic non-small cell
lung cancer that has failed prior
chemotherapy
Human Epidermal Growth Factor
Receptor Type 1/Epidermal Growth
Factor Receptor (HER1/EGFR) tyrosine
kinase inhibitor
Introduction
4. Lung Cancer
Two general types of lung cancer exist:
• Non-small cell lung cancer (NSCLC)
• Small cell lung cancer
The most common type of lung
cancer is NSCLC. Approximately
147,000 new cases of NSCLC
were reported in the United
States in 2004.
Introduction
5. Non-small cell lung cancer (NSCLC)
Comprises 85% of lung cancer
High mortality
Most patients present with
advanced disease:
• ~20% stage IIIA/IIIB
(poor prognosis)
• >50% stage IV disease
(limited to treatment option)
Introduction
6. Tumors with HER1/EGFR Dysregulation
• Many solid tumors have
dysregulated HER1/EGFR
• This association of
HER1/EGFR and tumor
development has been
shown in hormone-
sensitive tumors
(breast and prostate),and also in tumors that
are not hormone-dependent (e.g. head and
neck,
NSCLC, colon, ovarian, and glioma).
Introduction
7. HER1/EGFR Expression in Lung
Normal lung tissue
Low/no HER1/EGFR
Small-cell lung cancer
Low/no HER1/EGFRNSCLC
50-90%
Introduction
8. Epidermal growth factor receptor
(EGFR)
HER2
HER1/EGFR
HER3
HER4
A receptor tyrosine
kinase
Four members in its
family
ทำำหน้ำที่เป็น receptorต่อ
growth factor ligand
อยู่บนผิวของ cell ปกติ
และพบมำกที่ cellมะเร็ง
Introduction
9. HER1/EGFR
HER1/EGFR is made up of 3 parts
•intracellular tyrosine kinase domain
•short transmembrane domain
•extracellular ligand-binding domain
Introduction
10. Effects of HER1/EGFR Activation
cell proliferationCell growth
Various cellular effect
Ligand binding
Receptor
dimerization
Activated
tyrosine kinase
Induce
phosphorylation
Signal
transduction
P P
Introduction
11. HER family of receptors
and the role of HER1/EGFR
Introduction
12. Dysregulation of HER1/EGFR
Inhibition of
apoptosis
Proliferation
Invasion/metastasis
Angiogenesis
(development of tumor
vascular)
Introduction
20. Pharmacokinetics
A: bioavailability ≈ 60%; food ↑
bioavailability to almost 100%
D: ≈ 93% protein bound to albumin
and alpha-1 acid glycoprotein
M: primarily by CYP3A4 and to a
lesser extent by CYP1A2
E: mainly fecal (> 80%); t½= 36h
21. Drug Interactions
CYP3A4 inhibitors expected to
increase exposure to erlotinib:
ketoconazole increased AUC by
67%
CYP3A4 inducers expected to
decrease exposure to erlotinib:
rifampicin increased clearance by
3-fold and reduced AUC by 67%
23. Monitoring
Monitor for acute onset of new or
progressive pulmonary symptoms
such as dyspnea, cough, or fever
If interstitial lung disease is
diagnosed, discontinue erlotinib
Consider dose adjustment with
severe LFT changes (AST,ALT, Bili,
Alk Phos)
24. Prescription Information
Standard dose is 150 mg po daily taken
at least one hour before or two hours
after the ingestion of food
Cost: #30 150 mg tablets $2125.02
25. Summary
Tarceva™, erlotinib, is a Human Epidermal
Growth Receptor Type 1/ Epidermal growth
Factor Receptor (HER1/EGFR) tyrosine
kinase inhibitor.
Tarceva™ is indicated for the treatment of
patients with locally advanced or metastatic
non small cell lung cancer (NSCLC) after
failure of at least one prior chemotherapy
regimen.
26. Summary
Dermatologic and GI side effects are common.
The incidence of Interstitial Lung Disease was
the same as the placebo group (0.8%) in one
trial.